Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Kaneto Uekama

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Concepts & Ideas

Living Beings

Phenomena

Physiology

Intestinal Absorption

Occupations

Pharmaceutical Chemistry

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
83
Hirayama, Fumitoshi
61
Arima, Hidetoshi
28
Irie, Tetsumi
10
Motoyama, Keiichi
6
Okimoto, Kazuto
6
Stella, Valentino
6
Tsutsumi, Toshihito
6
Yano, Hideki
5
Miyake, K
5
Rajewski, Roger
4
Yunomae, Kiyokazu
4
Irie, Tetsumi
3
Kihara, Fumihiro
3
Kimura, K
3
Nagase, Yukihiko

Sign-in to see all Coauthors

Publications

TOP 3
Motoyama Keiichi; Nagatomo Kiyoshi; Abd Elazim Soliman Osama; Hirayama Fumitoshi; Uekama Kaneto; Arima Hidetoshi
Potential use of 2-hydroxypropyl-beta-cyclodextrin for preparation of orally disintegrating tablets containing dl-alpha-tocopheryl acetate, an oily drug.
Motoyama Keiichi; Kameyama Kazuhisa; Onodera Risako; Araki Norie; Hirayama Fumitoshi; Uekama Kaneto; Arima Hidetoshi
Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-beta-cyclodextrin, not 2,6-di-O-methyl-alpha-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells.
Higashi Taishi; Nishimura Katsunori; Yoshimatsu Ayumi; Ikeda Haruna; Arima Kanako; Motoyama Keiichi; Hirayama Fumitoshi; Uekama Kaneto; Arima Hidetoshi
Preparation of four types of coenzyme Q10/gamma-cyclodextrin supramolecular complexes and comparison of their pharmaceutical properties.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Kaneto Uekama (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Motoyama Keiichi; Nagatomo Kiyoshi; Abd Elazim Soliman Osama; Hirayama Fumitoshi; Uekama Kaneto; Arima Hidetoshi
Potential use of 2-hydroxypropyl-beta-cyclodextrin for preparation of orally disintegrating tablets containing dl-alpha-tocopheryl acetate, an oily drug.
Chemical & pharmaceutical bulletin 2009;57(11):1206-12.
2009: Motoyama Keiichi; Kameyama Kazuhisa; Onodera Risako; Araki Norie; Hirayama Fumitoshi; Uekama Kaneto; Arima Hidetoshi
Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-beta-cyclodextrin, not 2,6-di-O-methyl-alpha-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2009;38(3):249-61.
2009: Higashi Taishi; Nishimura Katsunori; Yoshimatsu Ayumi; Ikeda Haruna; Arima Kanako; Motoyama Keiichi; Hirayama Fumitoshi; Uekama Kaneto; Arima Hidetoshi
Preparation of four types of coenzyme Q10/gamma-cyclodextrin supramolecular complexes and comparison of their pharmaceutical properties.
Chemical & pharmaceutical bulletin 2009;57(9):965-70.
2009: Higashi Taishi; Hirayama Fumitoshi; Yamashita Shogo; Misumi Shogo; Arima Hidetoshi; Uekama Kaneto
Slow-release system of pegylated lysozyme utilizing formation of polypseudorotaxanes with cyclodextrins.
International journal of pharmaceutics 2009;374(1-2):26-32.
2009: Higashi Taishi; Hirayama Fumitoshi; Misumi Shogo; Motoyama Keiichi; Arima Hidetoshi; Uekama Kaneto
Polypseudorotaxane formation of randomly-pegylated insulin with cyclodextrins: slow release and resistance to enzymatic degradation.
Chemical & pharmaceutical bulletin 2009;57(5):541-4.
2009: Motoyama Keiichi; Toyodome Hiroshi; Onodera Risako; Irie Tetsumi; Hirayama Fumitoshi; Uekama Kaneto; Arima Hidetoshi
Involvement of lipid rafts of rabbit red blood cells in morphological changes induced by methylated beta-cyclodextrins.
Biological & pharmaceutical bulletin 2009;32(4):700-5.
2009: Motoyama Keiichi; Hashimoto Yosuke; Hirayama Fumitoshi; Uekama Kaneto; Arima Hidetoshi
Inhibitory effects of 2,6-di-O-methyl-alpha-cyclodextrin on poly I:C signaling in macrophages.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2009;36(2-3):285-91.
2008: Higashi Taishi; Hirayama Fumitoshi; Misumi Shogo; Arima Hidetoshi; Uekama Kaneto
Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system.
Biomaterials 2008;29(28):3866-71.
2008: Tsutsumi Toshihito; Hirayama Fumitoshi; Uekama Kaneto; Arima Hidetoshi
Potential use of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for short hairpin RNA-expressing plasmid DNA.
Journal of pharmaceutical sciences 2008;97(8):3022-34.
2008: Nishimura Katsunori; Higashi Taishi; Yoshimatsu Ayumi; Hirayama Fumitoshi; Uekama Kaneto; Arima Hidetoshi
Pseudorotaxane-like supramolecular complex of coenzyme Q10 with gamma-cyclodextrin formed by solubility method.
Chemical & pharmaceutical bulletin 2008;56(5):701-6.
2008: Iohara Daisuke; Hirayama Fumitoshi; Ishiguro Takako; Arima Hidetoshi; Uekama Kaneto
Preparation of amorphous indomethacin from aqueous 2,6-di-O-methyl-beta-cyclodextrin solution.
International journal of pharmaceutics 2008;354(1-2):70-6.
2008: Sekiya Noboru; Nishiwaki Atsushi; Nishiura Akio; Yamamoto Masanobu; Takeda Kazuhisa; Iohara Daisuke; Hirayama Fumitoshi; Arima Hidetoshi; Uekama Kaneto
Improved stability of Opalmon tablets under humid conditions IV: effect of polysaccharides and disintegrants on the stability and dissolution property of Opalmon tablets.
Chemical & pharmaceutical bulletin 2008;56(1):7-11.
2007: Anzai Kinsei; Mizoguchi Jun-ichi; Yanagi Toshiharu; Hirayama Fumitoshi; Arima Hidetoshi; Uekama Kaneto
Improvement of dissolution properties of a new Helicobacter pylori eradicating agent (TG44) by inclusion complexation with beta-cyclodextrin.
Chemical & pharmaceutical bulletin 2007;55(10):1466-70.
2007: Tsutsumi Toshihito; Hirayama Fumitoshi; Uekama Kaneto; Arima Hidetoshi
Evaluation of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA).
Journal of controlled release : official journal of the Controlled Release Society 2007;119(3):349-59.
2007: Higashi Taishi; Hirayama Fumitoshi; Arima Hidetoshi; Uekama Kaneto
Polypseudorotaxanes of pegylated insulin with cyclodextrins: application to sustained release system.
Bioorganic & medicinal chemistry letters 2007;17(7):1871-4.
2006: Tavornvipas Sumitra; Hirayama Fumitoshi; Takeda Seiko; Arima Hidetoshi; Uekama Kaneto
Effects of cyclodextrins on chemically and thermally induced unfolding and aggregation of lysozyme and basic fibroblast growth factor.
Journal of pharmaceutical sciences 2006;95(12):2722-9.
2006: Arima Hidetoshi; Chihara Yuko; Arizono Masayo; Yamashita Shogo; Wada Koki; Hirayama Fumitoshi; Uekama Kaneto
Enhancement of gene transfer activity mediated by mannosylated dendrimer/alpha-cyclodextrin conjugate (generation 3, G3).
Journal of controlled release : official journal of the Controlled Release Society 2006;116(1):64-74.
2006: Motoyama Keiichi; Arima Hidetoshi; Toyodome Hiroshi; Irie Tetsumi; Hirayama Fumitoshi; Uekama Kaneto
Effect of 2,6-di-O-methyl-alpha-cyclodextrin on hemolysis and morphological change in rabbit's red blood cells.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2006;29(2):111-9.
2006: Hara Takumi; Arima Hidetoshi; Hirayama Fumitoshi; Uekama Kaneto
Enhanced bioavailability of a new thiazolidine derivative FPFS-410, an antidiabetic and lipid-lowering drug, after oral administration of its hydroxypropyl-beta-cyclodextrin complex to bile duct-cannulated rats.
Journal of pharmaceutical sciences 2006;95(8):1771-82.
2006: Arima Hidetoshi; Hagiwara Yoshiyuki; Hirayama Fumitoshi; Uekama Kaneto
Enhancement of antitumor effect of doxorubicin by its complexation with gamma-cyclodextrin in pegylated liposomes.
Journal of drug targeting 2006;14(4):225-32.
2006: Hara Takumi; Hirayama Fumitoshi; Arima Hidetoshi; Yamaguchi Yoshihiro; Uekama Kaneto
Improvement of solubility and oral bioavailability of 2-(N-cyanoimino)-5-[(E)-4-styrylbenzylidene]-4-oxothiazolidine (FPFS-410) with antidiabetic and lipid-lowering activities in dogs by 2-hydroxypropyl-beta-cyclodextrin.
Chemical & pharmaceutical bulletin 2006;54(3):344-9.
2006: Anzai Kinsei; Kono Hiroyuki; Mizoguchi Jun-ichi; Yanagi Toshiharu; Hirayama Fumitoshi; Arima Hidetoshi; Uekama Kaneto
Two-dimensional 13C-1H heteronuclear correlation NMR spectroscopic studies for the inclusion complex of cyclomaltoheptaose (beta-cyclodextrin) with a new Helicobacter pylori eradicating agent (TG44) in the amorphous state.
Carbohydrate research 2006;341(4):499-506.
2006: Sonoda Yoh; Hirayama Fumitoshi; Arima Hidetoshi; Yamaguchi Yoshihiro; Saenger Wolfram; Uekama Kaneto
Cyclodextrin-based isolation of Ostwald's metastable polymorphs occurring during crystallization.
Chemical communications (Cambridge, England) 2006;(5):517-9.
2006: Hagiwara Yoshiyuki; Arima Hidetoshi; Miyamoto Yuji; Hirayama Fumitoshi; Uekama Kaneto
Preparation and pharmaceutical evaluation of liposomes entrapping salicylic acid/gamma-cyclodextrin conjugate.
Chemical & pharmaceutical bulletin 2006;54(1):26-32.
2005: Arima Hidetoshi; Motoyama Keiichi; Matsukawa Akihiro; Nishimoto Yoji; Hirayama Fumitoshi; Uekama Kaneto
Inhibitory effects of dimethylacetyl-beta-cyclodextrin on lipopolysaccharide-induced macrophage activation and endotoxin shock in mice.
Biochemical pharmacology 2005;70(10):1506-17.
2005: Wada Koki; Arima Hidetoshi; Tsutsumi Toshihito; Chihara Yuko; Hattori Kenjiro; Hirayama Fumitoshi; Uekama Kaneto
Improvement of gene delivery mediated by mannosylated dendrimer/alpha-cyclodextrin conjugates.
Journal of controlled release : official journal of the Controlled Release Society 2005;104(2):397-413.
2005: Motoyama Keiichi; Arima Hidetoshi; Nishimoto Yoji; Miyake Kensuke; Hirayama Fumitoshi; Uekama Kaneto
Involvement of CD14 in the inhibitory effects of dimethyl-alpha-cyclodextrin on lipopolysaccharide signaling in macrophages.
FEBS letters 2005;579(7):1707-14.
2005: Wada Koki; Arima Hidetoshi; Tsutsumi Toshihito; Hirayama Fumitoshi; Uekama Kaneto
Enhancing effects of galactosylated dendrimer/alpha-cyclodextrin conjugates on gene transfer efficiency.
Biological & pharmaceutical bulletin 2005;28(3):500-5.
2004: Tavornvipas Sumitra; Tajiri Shinichiro; Hirayama Fumitoshi; Arima Hidetoshi; Uekama Kaneto
Effects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone.
Pharmaceutical research 2004;21(12):2369-76.
2004: Uekama Kaneto
[Pharmaceutical application of cyclodextrins as multi-functional drug carriers]
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 2004;124(12):909-35.
2004: Okimoto Kazuto; Tokunaga Yuji; Ibuki Rinta; Irie Tetsumi; Uekama Kaneto; Rajewski Roger A; Stella Valentino J
Applicability of (SBE)7m-beta-CD in controlled-porosity osmotic pump tablets (OPTs).
International journal of pharmaceutics 2004;286(1-2):81-8.
2004: Uekama Kaneto
Design and evaluation of cyclodextrin-based drug formulation.
Chemical & pharmaceutical bulletin 2004;52(8):900-15.
2004: Ikeda Yoichi; Hirayama Fumitoshi; Arima Hidetoshi; Uekama Kaneto; Yoshitake Yasuyuki; Harano Kazunobu
NMR spectroscopic characterization of metoprolol/cyclodextrin complexes in aqueous solution: cavity size dependency.
Journal of pharmaceutical sciences 2004;93(7):1659-71.
2004: Arima Hidetoshi; Yunomae Kiyokazu; Morikawa Tadatoshi; Hirayama Fumitoshi; Uekama Kaneto
Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-beta-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers.
Pharmaceutical research 2004;21(4):625-34.
2003: Nagase Yukihiko; Arima Hidetoshi; Wada Koki; Sugawara Tadaki; Satoh Hiroshi; Hirayama Fumitoshi; Uekama Kaneto
Inhibitory effect of sulfobutyl ether beta-cyclodextrin on DY-9760e-induced cellular damage: In vitro and in vivo studies.
Journal of pharmaceutical sciences 2003;92(12):2466-74.
2003: Kihara Fumihiro; Arima Hidetoshi; Tsutsumi Toshihito; Hirayama Fumitoshi; Uekama Kaneto
In vitro and in vivo gene transfer by an optimized alpha-cyclodextrin conjugate with polyamidoamine dendrimer.
Bioconjugate chemistry 2003;14(2):342-50.
2003: Yunomae Kiyokazu; Arima Hidetoshi; Hirayama Fumitoshi; Uekama Kaneto
Involvement of cholesterol in the inhibitory effect of dimethyl-beta-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells.
FEBS letters 2003;536(1-3):225-31.
2002: Tavornvipas Sumitra; Hirayama Fumitoshi; Arima Hidetoshi; Uekama Kaneto; Ishiguro Toshihiro; Oka Masahide; Hamayasu Kenichi; Hashimoto Hitoshi
6-O-alpha-(4-O-alpha-D-glucuronyl)-D-glucosyl-beta-cyclodextrin: solubilizing ability and some cellular effects.
International journal of pharmaceutics 2002;249(1-2):199-209.
2002: Kihara Fumihiro; Arima Hidetoshi; Tsutsumi Toshihito; Hirayama Fumitoshi; Uekama Kaneto
Effects of structure of polyamidoamine dendrimer on gene transfer efficiency of the dendrimer conjugate with alpha-cyclodextrin.
Bioconjugate chemistry 2002;13(6):1211-9.
2002: Ikeda Yoichi; Motoune Sohko; Matsuoka Toshikazu; Arima Hidetoshi; Hirayama Fumitoshi; Uekama Kaneto
Inclusion complex formation of captopril with alpha- and beta-cyclodextrins in aqueous solution: NMR spectroscopic and molecular dynamic studies.
Journal of pharmaceutical sciences 2002;91(11):2390-8.
2002: Nagase Y; Hirata M; Arima H; Tajiri S; Nishimoto Y; Hirayama F; Irie T; Uekama K
Protective effect of sulfobutyl ether beta-cyclodextrin on DY-9760e-induced hemolysis in vitro.
Journal of pharmaceutical sciences 2002;91(11):2382-9.
2002: Kamada Makoto; Hirayama Fumitoshi; Udo Koichi; Yano Hideki; Arima Hidetoshi; Uekama Kaneto
Cyclodextrin conjugate-based controlled release system: repeated- and prolonged-releases of ketoprofen after oral administration in rats.
Journal of controlled release : official journal of the Controlled Release Society 2002;82(2-3):407-16.
2002: Yano Hideki; Hirayama Fumitoshi; Kamada Makoto; Arima Hidetoshi; Uekama Kaneto
Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration.
Journal of controlled release : official journal of the Controlled Release Society 2002;79(1-3):103-12.
2001: Yano H; Hirayama F; Arima H; Uekama K
Prednisolone-appended alpha-cyclodextrin: alleviation of systemic adverse effect of prednisolone after intracolonic administration in 2,4,6-trinitrobenzenesulfonic acid-induced colitis rats.
Journal of pharmaceutical sciences 2001;90(12):2103-12.
2001: Uekama K; Hieda Y; Hirayama F; Arima H; Sudoh M; Yagi A; Terashima H
Stabilizing and solubilizing effects of sulfobutyl ether beta-cyclodextrin on prostaglandin E1 analogue.
Pharmaceutical research 2001;18(11):1578-85.
2001: Nagase Y; Hirata M; Wada K; Arima H; Hirayama F; Irie T; Kikuchi M; Uekama K
Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether beta-cyclodextrin.
International journal of pharmaceutics 2001;229(1-2):163-72.
2001: Arima H; Nishimoto Y; Motoyama K; Hirayama F; Uekama K
Inhibitory effects of novel hydrophilic cyclodextrin derivatives on nitric oxide production in macrophages stimulated with lipopolysaccharide.
Pharmaceutical research 2001;18(8):1167-73.
2001: Arima H; Kihara F; Hirayama F; Uekama K
Enhancement of gene expression by polyamidoamine dendrimer conjugates with alpha-, beta-, and gamma-cyclodextrins.
Bioconjugate chemistry 2001;12(4):476-84.
2001: Arima H; Yunomae K; Miyake K; Irie T; Hirayama F; Uekama K
Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats.
Journal of pharmaceutical sciences 2001;90(6):690-701.
2001: Arima H; Yunomae K; Hirayama F; Uekama K
Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.
The Journal of pharmacology and experimental therapeutics 2001;297(2):547-55.
2001: Ono N; Arima H; Hirayama F; Uekama K
A moderate interaction of maltosyl-alpha-cyclodextrin with Caco-2 cells in comparison with the parent cyclodextrin.
Biological & pharmaceutical bulletin 2001;24(4):395-402.
2001: Yano H; Hirayama F; Arima H; Uekama K
Preparation of prednisolone-appended alpha-, beta- and gamma-cyclodextrins: substitution at secondary hydroxyl groups and in vitro hydrolysis behavior.
Journal of pharmaceutical sciences 2001;90(4):493-503.
2001: Ono N; Hirayama F; Arima H; Uekama K
Analysis of the phase solubility diagram of a phenacetin/competitor/beta-cyclodextrin ternary system, involving competitive inclusion complexation.
Chemical & pharmaceutical bulletin 2001;49(1):78-81.
2000: Hirayama F; Ogata T; Yano H; Arima H; Udo K; Takano M; Uekama K
Release characteristics of a short-chain fatty acid, n-butyric acid, from its beta-cyclodextrin ester conjugate in rat biological media.
Journal of pharmaceutical sciences 2000;89(11):1486-95.
2000: Tokihiro K; Arima H; Tajiri S; Irie T; Hirayama F; Uekama K
Improvement of subcutaneous bioavailability of insulin by sulphobutyl ether beta-cyclodextrin in rats.
The Journal of pharmacy and pharmacology 2000;52(8):911-7.
2000: Yano H; Hirayama F; Arima H; Uekama K
Hydrolysis behavior of prednisolone 21-hemisuccinate/beta-cyclodextrin amide conjugate: involvement of intramolecular catalysis of amide group in drug release.
Chemical & pharmaceutical bulletin 2000;48(8):1125-8.
2000: Hirayama F; Honjo M; Arima H; Okimoto K; Uekama K
X-ray crystallographic characterization of nilvadipine monohydrate and its phase transition behavior.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2000;11(1):81-8.
2000: Kimura K; Hirayama F; Arima H; Uekama K
Effects of aging on crystallization, dissolution and absorption characteristics of amorphous tolbutamide-2-hydroxypropyl-beta-cyclodextrin complex.
Chemical & pharmaceutical bulletin 2000;48(5):646-50.
2000: Miyake K; Arima H; Hirayama F; Yamamoto M; Horikawa T; Sumiyoshi H; Noda S; Uekama K
Improvement of solubility and oral bioavailability of rutin by complexation with 2-hydroxypropyl-beta-cyclodextrin.
Pharmaceutical development and technology 2000;5(3):399-407.
1999: Kimura K; Hirayama F; Arima H; Uekama K
Solid-state 13C nuclear magnetic resonance spectroscopic study on amorphous solid complexes of tolbutamide with 2-hydroxypropyl-alpha- and -beta-cyclodextrins.
Pharmaceutical research 1999;16(11):1729-34.
1999: Hirayama F; Mieda S; Miyamoto Y; Arima H; Uekama K
Heptakis(2,6-di-O-methyl-3-O-acetyl)-beta-cyclodextrin: A water-soluble cyclodextrin derivative with low hemolytic activity.
Journal of pharmaceutical sciences 1999;88(10):970-5.
1999: Okimoto K; Ohike A; Ibuki R; Aoki O; Ohnishi N; Rajewski R A; Stella V J; Irie T; Uekama K
Factors affecting membrane-controlled drug release for an osmotic pump tablet (OPT) utilizing (SBE)(7m)-beta-CD as both a solubilizer and osmotic agent.
Journal of controlled release : official journal of the Controlled Release Society 1999;60(2-3):311-9.
1999: Ono N; Hirayama F; Arima H; Uekama K
Determination of stability constant of beta-cyclodextrin complexes using the membrane permeation technique and the permeation behavior of drug-competing agent-beta-cyclodextrin ternary systems.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 1999;8(2):133-9.
1999: Okimoto K; Ohike A; Ibuki R; Aoki O; Ohnishi N; Irie T; Uekama K; Rajewski R A; Stella V J
Design and evaluation of an osmotic pump tablet (OPT) for chlorpromazine using (SBE)7m-beta-CD.
Pharmaceutical research 1999;16(4):549-54.
1999: Kimura K; Hirayama F; Uekama K
Characterization of tolbutamide polymorphs (Burger's forms II and IV) and polymorphic transition behavior.
Journal of pharmaceutical sciences 1999;88(4):385-91.
1999: Miyake K; Irie T; Arima H; Hirayama F; Uekama K; Hirano M; Okamaoto Y
Characterization of itraconazole/2-hydroxypropyl-beta-cyclodextrin inclusion complex in aqueous propylene glycol solution.
International journal of pharmaceutics 1999;179(2):237-45.
1999: Miyake K; Arima H; Irie T; Hirayama F; Uekama K
Enhanced absorption of cyclosporin A by complexation with dimethyl-beta-cyclodextrin in bile duct-cannulated and -noncannulated rats.
Biological & pharmaceutical bulletin 1999;22(1):66-72.
1999: Miyake K; Hirayama F; Uekama K
Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-alpha- and -beta-cyclodextrins in aqueous solution.
Journal of pharmaceutical sciences 1999;88(1):39-45.
1998: Okimoto K; Miyake M; Ohnishi N; Rajewski R A; Stella V J; Irie T; Uekama K
Design and evaluation of an osmotic pump tablet (OPT) for prednisolone, a poorly water soluble drug, using (SBE)7m-beta-CD.
Pharmaceutical research 1998;15(10):1562-8.
1998: Minami K; Hirayama F; Uekama K
Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration.
Journal of pharmaceutical sciences 1998;87(6):715-20.
1998: Arima H; Miyaji T; Irie T; Hirayama F; Uekama K
Enhancing effect of hydroxypropyl-beta-cyclodextrin on cutaneous penetration and activation of ethyl 4-biphenylyl acetate in hairless mouse skin.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 1998;6(1):53-9.
1997: Uekama K; Minami K; Hirayama F
6A-O-[(4-biphenylyl)acetyl]-alpha-, -beta-, and -gamma-cyclodextrins and 6A-deoxy-6A-[[(4-biphenylyl)acetyl]amino]-alpha-, -beta-, and -gamma-cyclodextrins: potential prodrugs for colon-specific delivery.
Journal of medicinal chemistry 1997;40(17):2755-61.
1997: Tokihiro K; Irie T; Uekama K
Varying effects of cyclodextrin derivatives on aggregation and thermal behavior of insulin in aqueous solution.
Chemical & pharmaceutical bulletin 1997;45(3):525-31.
1997: Irie T; Uekama K
Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation.
Journal of pharmaceutical sciences 1997;86(2):147-62.
1996: Arima H; Miyaji T; Irie T; Hirayama F; Uekama K
Possible enhancing mechanism of the cutaneous permeation of 4-biphenylylacetic acid by beta-cyclodextrin derivatives in hydrophilic ointment.
Chemical & pharmaceutical bulletin 1996;44(3):582-6.
1996: Okimoto K; Rajewski R A; Uekama K; Jona J A; Stella V J
The interaction of charged and uncharged drugs with neutral (HP-beta-CD) and anionically charged (SBE7-beta-CD) beta-cyclodextrins.
Pharmaceutical research 1996;13(2):256-64.
1996: Kondo T; Irie T; Uekama K
Combination effects of alpha-cyclodextrin and xanthan gum on rectal absorption and metabolism of morphine from hollow-type suppositories in rabbits.
Biological & pharmaceutical bulletin 1996;19(2):280-6.
1996: Hirayama F; Minami K; Uekama K
In-vitro evaluation of biphenylyl acetic acid-beta-cyclodextrin conjugates as colon-targeting prodrugs: drug release behaviour in rat biological media.
The Journal of pharmacy and pharmacology 1996;48(1):27-31.
1995: Abe K; Irie T; Uekama K
Enhanced nasal delivery of luteinizing hormone releasing hormone agonist buserelin by oleic acid solubilized and stabilized in hydroxypropyl-beta-cyclodextrin.
Chemical & pharmaceutical bulletin 1995;43(12):2232-7.
1995: Sugiuchi H; Uji Y; Okabe H; Irie T; Uekama K; Kayahara N; Miyauchi K
Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin.
Clinical chemistry 1995;41(5):717-23.
1995: Horikawa T; Hirayama F; Uekama K
In-vivo and in-vitro correlation for delayed-release behaviour of a molsidomine/O-carboxymethyl-O-ethyl-beta-cyclodextrin complex in gastric acidity-controlled dogs.
The Journal of pharmacy and pharmacology 1995;47(2):124-7.
1995: Shiotani K; Uehata K; Irie T; Uekama K; Thompson D O; Stella V J
Differential effects of sulfate and sulfobutyl ether of beta-cyclodextrin on erythrocyte membranes in vitro.
Pharmaceutical research 1995;12(1):78-84.
1995: Uekama K; Kondo T; Nakamura K; Irie T; Arakawa K; Shibuya M; Tanaka J
Modification of rectal absorption of morphine from hollow-type suppositories with a combination of alpha-cyclodextrin and viscosity-enhancing polysaccharide.
Journal of pharmaceutical sciences 1995;84(1):15-20.
1994: Hirayama F; Wang Z; Uekama K
Effect of 2-hydroxypropyl-beta-cyclodextrin on crystallization and polymorphic transition of nifedipine in solid state.
Pharmaceutical research 1994;11(12):1766-70.
1994: Shiotani K; Uehata K; Irie T; Hirayama F; Uekama K
Characterization of the inclusion mode of beta-cyclodextrin sulfate and its effect on the chlorpromazine-induced hemolysis of rabbit erythrocytes.
Chemical & pharmaceutical bulletin 1994;42(11):2332-7.
1994: Uekama K; Horikawa T; Yamanaka M; Hirayama F
Peracylated beta-cyclodextrins as novel sustained-release carriers for a water-soluble drug, molsidomine.
The Journal of pharmacy and pharmacology 1994;46(9):714-7.
1994: Wang Z; Hirayama F; Uekama K
In-vivo and in-vitro evaluations of a modified-release oral dosage form of nifedipine by hybridization of hydroxypropyl-beta-cyclodextrin and hydroxypropylcelluloses in dogs.
The Journal of pharmacy and pharmacology 1994;46(6):505-7.
1993: Wang Z; Horikawa T; Hirayama F; Uekama K
Design and in-vitro evaluation of a modified-release oral dosage form of nifedipine by hybridization of hydroxypropyl-beta-cyclodextrin and hydroxypropylcellulose.
The Journal of pharmacy and pharmacology 1993;45(11):942-6.
1993: Matsuda H; Ito K; Sato Y; Yoshizawa D; Tanaka M; Taki A; Sumiyoshi H; Utsuki T; Hirayama F; Uekama K
Inclusion complexation of p-hydroxybenzoic acid esters with 2-hydroxypropyl-beta-cyclodextrins. On changes in solubility and antimicrobial activity.
Chemical & pharmaceutical bulletin 1993;41(8):1448-52.
1993: Uekama K; Shiotami K; Irie T; Ishimaru Y; Pitha J
Protective effects of cyclodextrin sulphates against gentamicin-induced nephrotoxicity in the rat.
The Journal of pharmacy and pharmacology 1993;45(8):745-7.
1993: Hirayama F; Kurihara M; Horiuchi Y; Utsuki T; Uekama K; Yamasaki M
Preparation of heptakis(2,6-di-O-ethyl)-beta-cyclodextrin and its nuclear magnetic resonance spectroscopic characterization.
Pharmaceutical research 1993;10(2):208-13.
1992: Adachi H; Irie T; Uekama K; Manako T; Yano T; Saita M
Inhibitory effect of prostaglandin E1 on laurate-induced peripheral vascular occlusive sequelae in rabbits: optimized topical formulation with beta-cyclodextrin derivative and penetration enhancer HPE-101.
The Journal of pharmacy and pharmacology 1992;44(12):1033-5.
1992: Arima H; Kondo T; Irie T; Uekama K
Enhanced rectal absorption and reduced local irritation of the anti-inflammatory drug ethyl 4-biphenylylacetate in rats by complexation with water-soluble beta-cyclodextrin derivatives and formulation as oleaginous suppository.
Journal of pharmaceutical sciences 1992;81(11):1119-25.
1992: Hirayama F; Yamamoto M; Uekama K
Acid-catalyzed hydrolysis of maltosyl-beta-cyclodextrin.
Journal of pharmaceutical sciences 1992;81(9):913-6.
1992: Hirayama F; Utsuki T; Uekama K; Yamasaki M; Harata K
Prominent inclusion effect of dimethyl-beta-cyclodextrin on photoisomerization of the thromboxane synthetase inhibitor (E)-4-(1-imidazoylmethyl)cinnamic acid.
Journal of pharmaceutical sciences 1992;81(8):817-22.
1992: Yamamoto M; Hirayama F; Uekama K
Improvement of stability and dissolution of prostaglandin E1 by maltosyl-beta-cyclodextrin in lyophilized formulation.
Chemical & pharmaceutical bulletin 1992;40(3):747-51.
1992: Uekama K; Ikegami K; Wang Z; Horiuchi Y; Hirayama F
Inhibitory effect of 2-hydroxypropyl-beta-cyclodextrin on crystal-growth of nifedipine during storage: superior dissolution and oral bioavailability compared with polyvinylpyrrolidone K-30.
The Journal of pharmacy and pharmacology 1992;44(2):73-8.
1992: Uekama K; Adachi H; Irie T; Yano T; Saita M; Noda K
Improved transdermal delivery of prostaglandin E1 through hairless mouse skin: combined use of carboxymethyl-ethyl-beta-cyclodextrin and penetration enhancers.
The Journal of pharmacy and pharmacology 1992;44(2):119-21.
1992: Arima H; Kondo T; Irie T; Hirayama F; Uekama K; Miyaji T; Inoue Y
[Use of water-soluble beta-cyclodextrin derivatives as carriers of anti-inflammatory drug biphenylylacetic acid in rectal delivery]
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 1992;112(1):65-72.
1991: Horiuchi Y; Hirayama F; Uekama K
[Improvement of stability and bioavailability of 1-hexylcarbamoyl-5-fluorouracil (HCFU) by O-carboxymethyl-O-ethyl-beta- cyclodextrin]
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 1991;111(10):592-9.
1990: Arima H; Adachi H; Irie T; Uekama K; Pitha J
Enhancement of the antiinflammatory effect of ethyl 4-biphenylyl acetate in ointment by beta-cyclodextrin derivatives: increased absorption and localized activation of the prodrug in rats.
Pharmaceutical research 1990;7(11):1152-6.
1990: Uekama K; Matsubara K; Abe K; Horiuchi Y; Hirayama F; Suzuki N
Design and in vitro evaluation of slow-release dosage form of piretanide: utility of beta-cyclodextrin:cellulose derivative combination as a modified-release drug carrier.
Journal of pharmaceutical sciences 1990;79(3):244-8.
1990: Horiuchi Y; Hirayama F; Uekama K
Slow-release characteristics of diltiazem from ethylated beta-cyclodextrin complexes.
Journal of pharmaceutical sciences 1990;79(2):128-32.
1990: Yoshida A; Yamamoto M; Itoh T; Irie T; Hirayama F; Uekama K
Utility of 2-hydroxypropyl-beta-cyclodextrin in an intramuscular injectable preparation of nimodipine.
Chemical & pharmaceutical bulletin 1990;38(1):176-9.
1989: Uekama K; Arima H; Irie T; Matsubara K; Kuriki T
Sustained release of buserelin acetate, a luteinizing hormone-releasing hormone agonist, from an injectable oily preparation utilizing ethylated beta-cyclodextrin.
The Journal of pharmacy and pharmacology 1989;41(12):874-6.
1989: Uekama K; Horiuchi Y; Irie T; Hirayama F
O-carboxymethyl-O-ethylcyclomaltoheptaose as a delayed-release-type drug carrier: improvement of the oral bioavailability of diltiazem in the dog.
Carbohydrate research 1989;192():323-30.
1989: Hoshino T; Ishida K; Irie T; Uekama K; Ono T
An attempt to reduce the photosensitizing potential of chlorpromazine with the simultaneous use of beta- and dimethyl-beta-cyclodextrins in guinea pigs.
Archives of dermatological research 1989;281(1):60-5.
1988: Horiuchi Y; Kikuchi M; Hirayama F; Uekama K; Ueno M; Ijitsu T
[Improvement of bioavailability of menaquinone-4 by dimethyl-beta-cyclodextrin complexation following oral administration]
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 1988;108(11):1093-100.
1988: Hirayama F; Hirashima N; Abe K; Uekama K; Ijitsu T; Ueno M
Utilization of diethyl-beta-cyclodextrin as a sustained-release carrier for isosorbide dinitrate.
Journal of pharmaceutical sciences 1988;77(3):233-6.
1987: Uekama K; Hirashima N; Horiuchi Y; Hirayama F; Ijitsu T; Ueno M
Ethylated beta-cyclodextrins as hydrophobic drug carriers: sustained release of diltiazem in the rat.
Journal of pharmaceutical sciences 1987;76(8):660-1.
1987: Arimori K; Uekama K
Effects of beta- and gamma-cyclodextrins on the pharmacokinetic behavior of prednisolone after intravenous and intramuscular administrations to rabbits.
Journal of pharmacobio-dynamics 1987;10(8):390-5.

Sign-in to see more